Shattuck Labs starts Phase 2b Crohn's trial for SL-325, plans HS study

Shattuck Labs announced on November 5, 2026 that it had started a Phase 2b trial called RECEPTIVE-CD1, testing SL-325 in patients with moderately to severely active Crohn's disease.¹ The trial is a randomized, double-blind, placebo-controlled study testing three dose levels of SL-325 against placebo in about 232 patients, split evenly across four arms, with the primary endpoint of endoscopic response at 12 weeks expected in the first half of 2028.¹

The company also said it plans to begin a second Phase 2 study, RECEPTIVE-HS1, in hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026.¹ That study is designed to randomize about 150 patients 1:1:1 across two SL-325 dose levels and placebo, with HiSCR50 response at Week 16 as the primary endpoint and data expected in the first half of 2028.¹ Shattuck said it had submitted an IND application to the FDA for this program in October 2026.¹

On the earlier-stage bispecific candidate, Shattuck presented preclinical data for SL-846 at UEG Week 2026, including results from a GLP toxicology study in non-human primates showing the drug was well tolerated up to 100 mg/kg, without evidence of DR3 or IL-23R agonism, with full blockade of TL1A-DR3 binding and IL-23 signaling, and a projected human antidrug antibody rate of 8 to 12 percent, supporting potential quarterly subcutaneous dosing.¹ The company said it expects to start a Phase 1 healthy volunteer trial of SL-846 and report initial data in 2027.¹

On finances, Shattuck reported cash, cash equivalents and short-term investments of $196.3 million as of September 30, 2026, compared with $86.1 million a year earlier.¹ The company said this cash position is expected to fund operations into 2029.¹